RU2012104843A - PHARMACEUTICAL COMPOSITION RIFAMPICINE - Google Patents
PHARMACEUTICAL COMPOSITION RIFAMPICINE Download PDFInfo
- Publication number
- RU2012104843A RU2012104843A RU2012104843/15A RU2012104843A RU2012104843A RU 2012104843 A RU2012104843 A RU 2012104843A RU 2012104843/15 A RU2012104843/15 A RU 2012104843/15A RU 2012104843 A RU2012104843 A RU 2012104843A RU 2012104843 A RU2012104843 A RU 2012104843A
- Authority
- RU
- Russia
- Prior art keywords
- mixture
- rifampicin
- piperine
- pharmaceutical composition
- starch
- Prior art date
Links
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title claims abstract 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 5
- 239000000203 mixture Substances 0.000 claims abstract 22
- 229960001225 rifampicin Drugs 0.000 claims abstract 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 15
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims abstract 12
- 229940075559 piperine Drugs 0.000 claims abstract 12
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims abstract 12
- 235000019100 piperine Nutrition 0.000 claims abstract 12
- 229920002472 Starch Polymers 0.000 claims abstract 8
- 235000019698 starch Nutrition 0.000 claims abstract 8
- 239000008107 starch Substances 0.000 claims abstract 8
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract 7
- 239000000843 powder Substances 0.000 claims abstract 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract 4
- 239000000314 lubricant Substances 0.000 claims abstract 4
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract 2
- 238000001035 drying Methods 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims abstract 2
- 239000008101 lactose Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 abstract 2
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 238000007599 discharging Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Пероральная фармацевтическая композиция рифампицина и пиперина с повышенной биодоступностью, содержащая рифампициновую смесь, пиперин и фармацевтически приемлемые эксципиенты, где рифампицин находится в порошковой форме с насыпной плотностью более 0,4 г/см, причем рифампициновая смесь изготовлена с использованием порошка рифампицина, крахмала и стеарата магния.2. Фармацевтическая композиция по п.1, где пиперин находится в форме таблетки.3. Способ изготовления пероральной фармацевтической композиции рифампицина и пиперина по п.1, включающий стадии:A) стадию приготовления рифампициновой смеси, включающую стадии:А1) смешивание порошка рифампицина и крахмала,А2) обработки смазывающими веществами смеси со стадии(А1) путем использования стеарата магния с получением рифампициновой смеси;B) стадию изготовления таблетки пиперина, включающую стадии:В1) грануляции смеси лактозы, крахмала и лаурилсульфата натрия с использованием крахмальной пасты с последующей сушкой и выгрузкой продукта,В2) смешивания пиперина и основных гранул со стадии (В1),В3) смешивания смеси со стадии (В2) с лаурилсульфатом натрия, натриевой солью кроскармелозы и коллоидным диоксидом кремния с последующей обработкой смазывающими веществами путем использования стеарата магния,В4) комкования смеси со стадии (В3) с последующей выгрузкой продукта,В5) обработки смазывающими веществами смеси со стадии (В4) путем использования коллоидного диоксида кремния и стеарата магния,В6) прессования смеси со стадии (В5) в таблетки;C) стадию обработки смеси со стадии (А) вместе с продуктом со стадии (В) с получением фармацевтической композиции рифампицина.1. An oral pharmaceutical composition of rifampicin and piperine with increased bioavailability, containing a rifampicin mixture, piperine and pharmaceutically acceptable excipients, where rifampicin is in powder form with a bulk density of more than 0.4 g/cm, and the rifampicin mixture is made using rifampicin powder, starch and magnesium stearate.2. Pharmaceutical composition according to claim 1, wherein the piperine is in the form of a tablet. A method for preparing an oral pharmaceutical composition of rifampicin and piperine according to claim 1, comprising the steps: A) the step of preparing a rifampicin mixture, comprising the steps of: A1) mixing the powder of rifampicin and starch, A2) treating the mixture with lubricants from step (A1) by using magnesium stearate with obtaining a rifampicin mixture; B) a piperine tablet manufacturing step, including the steps: B1) granulating a mixture of lactose, starch and sodium lauryl sulfate using a starch paste, followed by drying and unloading the product, B2) mixing piperine and basic granules from stage (B1), B3) mixing the mixture from step (B2) with sodium lauryl sulfate, croscarmellose sodium and colloidal silica, followed by lubricating by using magnesium stearate, B4) clumping the mixture from step (B3) followed by discharging the product, B5) lubricating the mixture from step (B4) by using colloidal silicon dioxide and stearate magnesium, B6) compressing the mixture from step (B5) into tablets; C) the step of processing the mixture from step (A) together with the product from step (B) to obtain a pharmaceutical composition of rifampicin.
Claims (3)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1698MU2009 | 2009-07-23 | ||
| IN1698/MUM/2009 | 2009-07-23 | ||
| PCT/IB2010/001777 WO2011010214A1 (en) | 2009-07-23 | 2010-07-22 | Pharmaceutical composition of rifampicin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012104843A true RU2012104843A (en) | 2013-08-27 |
Family
ID=43498820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012104843/15A RU2012104843A (en) | 2009-07-23 | 2010-07-22 | PHARMACEUTICAL COMPOSITION RIFAMPICINE |
Country Status (4)
| Country | Link |
|---|---|
| AP (1) | AP2012006117A0 (en) |
| RU (1) | RU2012104843A (en) |
| WO (1) | WO2011010214A1 (en) |
| ZA (1) | ZA201200531B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2906979T3 (en) * | 2016-12-21 | 2022-04-21 | Tioga Pharmaceuticals Inc | Solid pharmaceutical formulations of asimadoline |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650728B1 (en) * | 1993-10-29 | 2002-02-27 | Council of Scientific and Industrial Research | Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug |
| US5744161A (en) * | 1995-02-24 | 1998-04-28 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
| IN186315B (en) * | 1996-12-12 | 2001-08-04 | Panacea Biotec Ltd | |
| US7195769B2 (en) * | 2000-08-09 | 2007-03-27 | Panacea Biotec Limited | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| EA009214B1 (en) * | 2002-04-04 | 2007-12-28 | Индравадан Амбалал Моди | Pharmaceutical composition, a kit and method of treating hiv infections |
-
2010
- 2010-07-22 AP AP2012006117A patent/AP2012006117A0/en unknown
- 2010-07-22 RU RU2012104843/15A patent/RU2012104843A/en not_active Application Discontinuation
- 2010-07-22 WO PCT/IB2010/001777 patent/WO2011010214A1/en active Application Filing
-
2012
- 2012-01-23 ZA ZA2012/00531A patent/ZA201200531B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2012006117A0 (en) | 2012-02-29 |
| WO2011010214A1 (en) | 2011-01-27 |
| ZA201200531B (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2431473C2 (en) | New dosage form | |
| RU2019110089A (en) | ADVANCED MACHINE AND METHOD OF STRETCH FILM PACKAGING OF PRODUCTS SUPPLIED IN BLOCKS OR SEPARATE | |
| JP2009235073A5 (en) | ||
| RU2016152167A (en) | PHARMACEUTICAL PRODUCTS CONTAINING NITROCATECHIN DERIVATIVES AND METHODS FOR PRODUCING THEM | |
| RU2004123624A (en) | DRY GRANULATED AZITHROMYCIN COMPOSITIONS | |
| HRP20131088T1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| EP3606511B1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
| WO2015189386A1 (en) | Composition with a high drug load of sofosbuvir | |
| JP2016536285A (en) | Stable pharmaceutical composition comprising amlodipine and valsartan | |
| EP3150201B1 (en) | Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation | |
| RU2015117523A (en) | COMBINED DRUG CONTAINING HEMIGLIPTIN AND METFORMIN AND METHOD FOR PRODUCING IT | |
| RU2675844C2 (en) | Enteric coated tablet | |
| RU2012104843A (en) | PHARMACEUTICAL COMPOSITION RIFAMPICINE | |
| JP2010202579A (en) | Acarbose-containing disintegrating preparation in oral cavity | |
| EP3632436B1 (en) | Pharmaceutical composition comprising lenvatinib salts | |
| JP2018172359A (en) | Ezetimibe-containing tablet that comprises adequate amount of vinylpyrrolidone polymer | |
| CN102552170A (en) | Solid preparation taking prasugrel benzene sulfonate as active component | |
| Reddy et al. | Formulation and evaluation of immediate release tablets of linezolid | |
| JP2019089758A (en) | Method for improving dissolution in celecoxib-containing tablets | |
| EP3397285B1 (en) | Tablet formulations of montelukast sodium and rupatadine fumarate | |
| CN105030707A (en) | Method for preparing clotrimazole buccal tablets on basis of all-powder direct pressing of modified glucose | |
| RU2015101769A (en) | COMBINED DRUG LERCANIDIPINE AND ATORVASTATIN | |
| KR101509489B1 (en) | Method for preparing solid oral formulation comprising valsartan | |
| RU2013107724A (en) | PHARMACEUTICAL COMPOSITIONS OF MONTELUKAST AND LEVOCETIRISINE | |
| EP2682104A1 (en) | Orally-disintegrating formulations of dexketoprofen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150428 |